Journal
JOURNAL OF BIOLOGICAL CHEMISTRY
Volume 295, Issue 27, Pages 8887-8900Publisher
ELSEVIER
DOI: 10.1074/jbc.RA120.013042
Keywords
CBFA2; all-trans-retinoic acid (ATRA); acute myeloid leukemia (AML); cell differentiation; gene transcription; transcriptional corepressor; histone acetyltransferase; histone acetylation; chromatin accessibility; epigenetics; cancer biology; nuclear receptor; transcription corepressor; chromatin immunoprecipitation (ChIP); chromatin regulation
Categories
Funding
- National Institutes of Health [R01HL093195, R21CA178513, T32GM008306-26A1]
- Saint Louis University
- Brennan Summer Fellowship Award from Saint Louis University
Ask authors/readers for more resources
CBFA2/RUNX1 partner transcriptional co-repressor 3 (CBFA2T3, also known as MTG16 or ETO2) is a myeloid translocation gene family protein that functions as a master transcriptional corepressor in hematopoiesis. Recently, it has been shown that CBFA2T3 maintains leukemia stem cell gene expression and promotes relapse in acute myeloid leukemia (AML). However, a role for CBFA2T3 in myeloid differentiation of AML has not been reported. Here, we show that CBFA2T3 represses retinoic acid receptor (RAR) target gene expression and inhibits all-trans-retinoic acid (ATRA)-induced myeloid differentiation of AML cells. ChIP-Seq revealed that CBFA2T3 targets the RAR alpha/RXR alpha cistrome in U937 AML cells, predominantly at myeloid-specific enhancers associated with terminal differentiation. CRISPR/Cas9-mediated abrogation of CBFA2T3 resulted in spontaneous and ATRA-induced activation of myeloid-specific genes in a manner correlated with myeloid differentiation. Importantly, these effects were reversed by CBFA2T3 re-expression. Mechanistic studies showed that CBFA2T3 inhibits RAR target gene transcription by acting at an early step to regulate histone acetyltransferase recruitment, histone acetylation, and chromatin accessibility at RAR? target sites, independently of the downstream, RAR-mediated steps of transcription. Finally, we validated the inhibitory effect of CBFA2T3 on RAR in multiple AML subtypes and patient samples. To our knowledge, this is the first study to show that CBFA2T3 down-regulation is both necessary and sufficient for enhancing ATRA-induced myeloid gene expression and differentiation of AML cells. Our findings suggest that CBFA2T3 can serve as a potential target for enhancing AML responsiveness to ATRA differentiation therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available